Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04396457 | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | unknown | Phase 2 | 50 | National Hospital Organization Nagoya Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT04992715 | PD-L1 Expression in Lung Cancer(PELICAN) | unknown | Phase 2 | 15 | NanoMab Technology (UK) LimitedINDUSTRY | 1 | Mar 22, 2023 |
| NCT05778045 | Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 21, 2023 | clinicaltrials |
| NCT04519983 | Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs | unknown | Phase 2 | 40 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05620199 | Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy(UPLAN-I) | unknown | N/A | 20 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT05633342 | Project CADENCE (CAncer Detected Early caN be CurEd)(CADENCE) | unknown | — | 15,000 | MiRXES Pte LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04391283 | First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | unknown | — | 150 | Maastricht University Medical CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05771207 | Effects of Protein on Muscle, Gut Microbiota and Clinical Outcome in Patients With Lung Cancer-related Sarcopenia | unknown | N/A | 90 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05770063 | Effect of Compound Amino Acid Tablets on Nutritional Status of Patients With Lung Cancer | unknown | N/A | 86 | Beijing Chest HospitalOTHER | 0 | Mar 15, 2023 | clinicaltrials |
| NCT04703153 | LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)(LIQUIK) | unknown | — | 151 | Lucence Health Inc.INDUSTRY | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05761977 | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer(DRIVE) | unknown | — | 50 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05127382 | Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer | unknown | — | 40 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04338620 | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC | unknown | Phase 2 | 94 | Tang-Du HospitalOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05754736 | Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations. | unknown | Phase 2 | 50 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05746598 | Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients | unknown | — | 178 | Ain Shams UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05741021 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 84 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05738317 | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment | unknown | Phase 2 | 45 | Xiaorong DongOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04811001 | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations(CAPLAND) | unknown | Phase 2 | 170 | Fondazione Ricerca TraslazionaleOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05736991 | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | unknown | — | 600 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05737589 | Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis | unknown | — | 50 | Xiaorong DongOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04107168 | Microbiome Immunotherapy Toxicity and Response Evaluation | unknown | — | 1,800 | CCTU- Cancer ThemeOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04153097 | Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC | unknown | — | 500 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05445310 | Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer | unknown | Phase 2 | 114 | Peking Union Medical College HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04996927 | 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC | unknown | — | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05257512 | Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 150 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05430386 | Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC | unknown | Phase 1 | 174 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05533086 | PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer | unknown | — | 20 | Xiaohua ZhuOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05725915 | Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC | unknown | — | 56 | Beijing Red Clove Public Welfare Development CenterOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05715398 | BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 90 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 0 | Feb 10, 2023 | clinicaltrials |
| NCT05425134 | Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer | unknown | — | 5,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05716672 | Impact of Lazertinib Dose Modification on Effectiveness and Safety | unknown | — | 200 | Pusan National University HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05674227 | Cost-effectiveness Evaluation of Robotic Surgery in the Removal of Lung Lesions in the ATS of Milan | unknown | — | 5,400 | Agenzia di Tutela della Salute della Città Metropolitana di MilanoOTHER_GOV | 0 | Feb 1, 2023 | clinicaltrials |
| NCT05707585 | Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage | unknown | — | 2,064 | The Second Affiliated Hospital of Dalian Medical UniversityOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05068973 | Evaluation of the NOVATECH ® LUCIOLA TM EB Fiducial Marker During Radiotherapy Sessions in Lung Cancer Patients(LUCIOLA) | unknown | N/A | 35 | Hospital St. Joseph, Marseille, FranceOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05701384 | Lazertinib 160mg in EGFR T790M NSCLC | unknown | Phase 2 | 117 | Samsung Medical CenterOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02301858 | Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases | unknown | N/A | 100 | Janna BergOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02428049 | Radiation Pneumonitis After SBRT for NSCLC | unknown | — | 105 | Sykehuset i Vestfold HFOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05689437 | MIRA Clinical Learning Environment (MIRACLE): Lung(MIRACLE) | unknown | — | 1,000 | University Health Network, TorontoOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04162691 | Single Cell Sequencing Analysis of Thymoma | unknown | — | 10 | Zhejiang Cancer HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05545085 | Thoracoscopic Laser Speckle Contrast Imaging for Segment Resections(PORTION-I) | unknown | — | 10 | Frisius Medisch CentrumOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Mar 23, 2023source: clinicaltrials